These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 29597186

  • 1. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function.
    Raptis V, Bakogiannis C, Loutradis C, Boutou AK, Lampropoulou I, Intzevidou E, Sioulis A, Balaskas E, Sarafidis PA.
    Am J Nephrol; 2018; 47(4):231-238. PubMed ID: 29597186
    [Abstract] [Full Text] [Related]

  • 2. Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function.
    Raptis V, Bakogiannis C, Loutradis C, Boutou AK, Sioulis A, Balaskas E, Zebekakis P, Sarafidis PA.
    Kidney Blood Press Res; 2018; 43(3):744-754. PubMed ID: 29794429
    [Abstract] [Full Text] [Related]

  • 3. Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function.
    Raptis V, Loutradis C, Boutou AK, Faitatzidou D, Sioulis A, Ferro CJ, Papagianni A, Sarafidis PA.
    Cardiorenal Med; 2020; 10(6):440-451. PubMed ID: 33202410
    [Abstract] [Full Text] [Related]

  • 4. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M, Inci A.
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [Abstract] [Full Text] [Related]

  • 5. Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease.
    Raptis V, Georgianos PI, Sarafidis PA, Sioulis A, Makedou K, Makedou A, Grekas DM, Kapoulas S.
    Kidney Blood Press Res; 2013 Jul; 38(1):72-82. PubMed ID: 24577239
    [Abstract] [Full Text] [Related]

  • 6. Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease.
    Theodorakopoulou M, Raptis V, Loutradis C, Sarafidis P.
    Semin Nephrol; 2019 Nov; 39(6):599-612. PubMed ID: 31836042
    [Abstract] [Full Text] [Related]

  • 7. Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.
    Kocyigit I, Yilmaz MI, Orscelik O, Sipahioglu MH, Unal A, Eroglu E, Kalay N, Tokgoz B, Axelsson J, Oymak O.
    Nephron Clin Pract; 2013 Nov; 123(3-4):157-64. PubMed ID: 23887359
    [Abstract] [Full Text] [Related]

  • 8. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L, Radosevic A, Quintian C, Montañés R, Gràcia S, Vilaplana C, Mojal S, Ballarin JA, Fernández-Llama P, Torra R, Pascual J.
    PLoS One; 2017 Nov; 12(3):e0174583. PubMed ID: 28346513
    [Abstract] [Full Text] [Related]

  • 9. Exercise capacity in polycystic kidney disease.
    Reinecke NL, Cunha TM, Heilberg IP, Higa EM, Nishiura JL, Neder JA, Almeida WS, Schor N.
    Am J Kidney Dis; 2014 Aug; 64(2):239-46. PubMed ID: 24787761
    [Abstract] [Full Text] [Related]

  • 10. Systemic Succinate, Hypoxia-Inducible Factor-1 Alpha, and IL-1β Gene Expression in Autosomal Dominant Polycystic Kidney Disease with and without Hypertension.
    Kocyigit I, Taheri S, Eroglu E, Sener EF, Zararsız G, Uzun I, Tufan E, Mehmetbeyoglu E, Korkmaz Bayramov K, Sipahioglu MH, Ozkul Y, Tokgoz B, Oymak O, Axelsson J.
    Cardiorenal Med; 2019 Aug; 9(6):370-381. PubMed ID: 31319406
    [Abstract] [Full Text] [Related]

  • 11. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease.
    Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS.
    Am J Kidney Dis; 2008 Feb; 51(2):184-91. PubMed ID: 18215696
    [Abstract] [Full Text] [Related]

  • 12. Endothelial dysfunction and angiogenesis in autosomal dominant polycystic kidney disease.
    Fick-Brosnahan GM.
    Curr Hypertens Rev; 2013 Feb; 9(1):32-6. PubMed ID: 23971642
    [Abstract] [Full Text] [Related]

  • 13. Hypoxia-Inducible Factor 1α (HIF-1α), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease.
    Rahbari-Oskoui FF, Chapman AB.
    Am J Nephrol; 2018 Feb; 47(4):228-230. PubMed ID: 29597208
    [No Abstract] [Full Text] [Related]

  • 14. Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease.
    Reed BY, Masoumi A, Elhassan E, McFann K, Cadnapaphornchai MA, Maahs DM, Snell-Bergeon JK, Schrier RW.
    Kidney Int; 2011 Jan; 79(1):128-34. PubMed ID: 20881939
    [Abstract] [Full Text] [Related]

  • 15. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
    Messchendorp AL, van Londen M, Taylor JM, de Borst MH, Navis G, Casteleijn NF, Gaillard CAJM, Bakker SJL, Gansevoort RT, DIPAK Consortium.
    Clin J Am Soc Nephrol; 2018 Nov 07; 13(11):1680-1692. PubMed ID: 30254028
    [Abstract] [Full Text] [Related]

  • 16. The association of endothelin-1 levels with renal survival in polycystic kidney disease patients.
    Kocyigit I, Eroglu E, Kaynar AS, Kocer D, Kargi S, Zararsiz G, Bayramov R, Imamoglu H, Sipahioglu MH, Tokgoz B, Dundar M, Oymak O.
    J Nephrol; 2019 Feb 07; 32(1):83-91. PubMed ID: 30022320
    [Abstract] [Full Text] [Related]

  • 17. Copeptin levels and kidney function in ADPKD: case-control study.
    Corradi V, Martino F, Gastaldon F, Scalzotto E, Caprara C, Fortunato A, Pinaffo G, Marchetti C, Fabbi F, Giavarina D, Ferrari F, Rosner MH, Ronco C.
    Clin Nephrol; 2016 Sep 07; 86(9):147-53. PubMed ID: 27487355
    [Abstract] [Full Text] [Related]

  • 18. Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease.
    Ekinci İ, Buyukkaba M, Cinar A, Tunc M, Cebeci E, Gursu M, Kazancioglu R.
    Cureus; 2021 Feb 25; 13(2):e13561. PubMed ID: 33815976
    [Abstract] [Full Text] [Related]

  • 19. Urinary biomarkers at early ADPKD disease stage.
    Petzold K, Poster D, Krauer F, Spanaus K, Andreisek G, Nguyen-Kim TD, Pavik I, Ho TA, Serra AL, Rotar L.
    PLoS One; 2015 Feb 25; 10(4):e0123555. PubMed ID: 25875363
    [Abstract] [Full Text] [Related]

  • 20. Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease.
    Lai S, Mittherhofer AP, Cianci R, Riviello L, Vocaturi M, Mastroluca D, Ciccariello M, Von Heland M, Ricciuti GP, Salciccia S, Mazzaferro S.
    Eur Rev Med Pharmacol Sci; 2019 Apr 25; 23(7):2734-2743. PubMed ID: 31002123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.